DOCSLIB.ORG

WO 2016/071856 Al 12 May 2016 (12.05.2016) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2016/071856 Al 12 May 2016 (12.05.2016) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/071856 Al 12 May 2016 (12.05.2016) P O P C T (51) International Patent Classification: (74) Agent: RAYMOND, Daniel E ; c/o Novartis Pharmaceut C07K 7/64 (2006.01) A61P 35/00 (2006.01) icals Corporation, IP Services Mail Data, One Health Plaza A61K 38/12 (2006.01) 101/2, East Hanover, New Jersey 07936 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/IB2015/058537 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 5 November 20 15 (05 .11.20 15) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/076,023 6 November 2014 (06. 11.2014) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US) : NO- VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (84) Designated States (unless otherwise indicated, for every (CH). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventors; and TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicants (for US only): GRUNEWALD, Jan [DE/US]; TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Novartis Institute for Functional Genomics, Inc., Genomics DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Institute of the Novartis Research Foundation (GNF), LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 10675 John Jay Hopkins Drive, San Diego, California SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 9212 1 (US). JIN, Yunho [KR/US]; Novartis Institute for GW, KM, ML, MR, NE, SN, TD, TG). Functional Genomics, Inc., Genomics Institute of the No vartis Research (GNF), 10675 John Jay Hopkins Drive, Declarations under Rule 4.17 : San Diego, California 92 121 (US). OU, Weijia [US/US]; — as to applicant's entitlement to apply for and be granted a Novartis Institute for Functional Genomics, Inc., Genomics patent (Rule 4.1 7(H)) Institute of the Novartis Research (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). UNO, Published: Tetsuo [JP/US]; Novartis Institute for Functional Genom — with international search report (Art. 21(3)) ics, Inc., Genomics Institute of the Novartis Research — with sequence listing part of description (Rule 5.2(a)) (GNF), 10675 John Jay Hopkins Drive, San Diego, Cali fornia 92121 (US). (54) Title: AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE FIG. 4 00 © † Days Post Implantation (57) Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA poly o merase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceut ical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunocon - jugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates: Formula (I). AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62/076023, filed 06 November 201 4 , which is incorporated by reference herein in its entirety. F IELD OF THE INVENTION The invention relates to amatoxins and conjugates of amatoxins to a target-binding moiety, e.g. an antibody, and the use of such conjugates to treat cancer. BACKGROUND Amatoxins are cyclic peptides comprised of eight amino acid units which can be prepared synthetically, or can be isolated from a variety of mushroom species, such as Amanita phalloides (green death cap mushroom), Amanita bisporigera (destroying angel) , Amanita ocreata (destroying angel) , Amanita virosa (destroying angel) , Amanita bisporigera (fool's mushroom), Lepiota brunneo-incamata (deadly dapperling), Conocybe tiiaris and Galerina marginata. There are currently ten known members of the Amatoxin Family: alpha-Amanitin , beta-Amanitin , gamma-Amanitin, epsilon-Amanitin , Amanullin , Amanullinic acid, Amaninamide, Amanin and Proamanullin. Different mushroom species contain varying amounts of different Amatoxin family members. Amatoxins are potent and selective inhibitors of RNA polymerase II, a vital enzyme in the synthesis of messenger RNA (mRNA), microRNA, and small nuclear RNA (sn RNA). By inhibiting the synthesis of mRNA, Amatoxins thereby stop cell metabolism by inhibiting transcription and protein biosynthesis, which results in cellular apoptosis. Consequently Amatoxins stop cell growth and proliferation. Alpha-amanitin, is known to be an extremely potent inhibitor of eukaryotic RNA polymerase II (EC2.7.7.6) and to a lesser degree, RNA polymerase II I, thereby inhibiting transcription and protein biosynthesis. Wieland ( 1983) Int. J. Pept. Protein Res. 22(3) :257-276. Alpha-amanitin binds non-covalently to RNA polymerase II and dissociates slowly, making enzyme recovery unlikely. The use of antibody-drug conjugates (ADCs) for the targeted delivery of cell proliferation inhibitors and/or cytotoxic agents to specific cells has been the focus of significant research. Antibody-Drug Conjugate, Methods in Molecular Biology, Vol. 1045, Editor L . Ducry, Humana Press (201 3). ADCs include an antibody selected for its ability to bind to a cell targeted for therapeutic intervention , linked to a drug selected for its cytostatic or cytotoxic activity. Binding of the antibody to the targeted cell thereby delivers the drug to the site where its therapeutic effect is needed. Many antibodies that recognize and selectively bind to targeted cells, like cancer cells, have been disclosed for use in ADCs, and many methods for attaching payload (drug) compounds such as cytotoxins to antibodies have also been described. In spite of the extensive work on ADCs, though, only a few classes of cell proliferation inhibitors have been used extensively as ADC payloads. Even though the first ADC approved for use in humans in the U.S. was launched in 2000 (and later withdrawn from the market), a decade later only a few chem ical classes of drug compounds (maytansinoids, auristatins, calicheamycins and duocarmycins) had reached clinical trials as payloads for ADCs. Antibody-Drug Conjugates: the Next Generation of Moving Parts, A . Lash, Start-Up , Dec. 201 1, 1-6. The use of amatoxins as cytotoxic moieties in ADC's for tumour therapy was explored in 1981 (Davis & Preston, Science 1981 , 2 13 , 1385-1 388) by coupling an anti-Thy 1.2 antibody to alpha-amanitin using a linker attached to the 7' position of the indole ring via diazotation. Morris & Venton (Morris & Venton, Int. J. Peptide Protein Res. 1983, 2 1 4 19- 430) also demonstrated that substitution at the 7' position resulted in a derivative which maintained cytotoxic activity. Patent application EP 1 859 8 1 1 A 1 (published November 28, 2007) described the direct conjugation (i.e. without a linker structure) of albumin or a monoclonal antibody (HEA1 25, OKT3, or PA-1) to the gamma C-atom of amatoxin amino acid 1 of beta- amanitin . The inhibitory effect of these conjugates on the proliferation of breast cancer cells (MCF-7), Burkitt's lymphoma cells (Raji), and Tlymphoma cells (Jurkat) was shown. The use of linkers was suggested, however no such constructs were exemplified and no details regarding linker attachment sites on Amatoxins were provided. Patent applications WO 201 0/1 15629 and WO 201 0/1 15630 (both published October 14 , 201 0) describe conjugates, where antibodies, such as antiEpCAM antibodies such as humanized antibody huHEA1 25, are coupled to amatoxins via (i) the gamma C-atom of amatoxin amino acid 1, (ii) the 6' C-atom of amatoxin amino acid 4 , or (iii) via the delta C- atom of amatoxin amino acid 3 , in each case either directly or via a linker between the antibody and the amatoxins. The inhibitory effects of these conjugates on the proliferation of breast cancer cells (cell line MCF-7), pancreatic carcinoma (cell line Capan-1 ) , colon cancer (cell line Colo205) and cholangiocarcinoma (cell line OZ) were shown. Patent applications WO 201 2/1 19787 (published September 13 , 201 2) describes conjugating a target-binding moiety via a linker attached to the amatoxin indole nitrogen. The cytotoxic activity of such conjugates on a HER2-positive tumor cell line in vitro was disclosed. Patent applications WO 201 4/043403 (published March 20, 201 4) describes conjugating a target-binding moiety via a linker attached to the T position of the amatoxin indole. The cytotoxic activity of such conjugates on Herceptin and lgG1 in MDA-MB-468 cells was disclosed. Also, the cytotoxic activity of such conjugates on Herceptin in PC3, HCC-1 954 and MDA-MB-46 cells was disclosed. In view of the toxicity of amatoxins, particularly for liver cells, it is important that ADC's comprising a linked amatoxin remain highly stable in plasma prior to the release of the amatoxin after internalization into the target cells. In this regard, improvements of the conjugate stability may have drastic consequences for the therapeutic window and the safety of the amatoxin conjugates for therapeutic approaches.
Load more

Recommended publications
  • Meeting Key Synthetic Challenges in Amanitin Synthesis with a New Cytotoxic Analog: 50-Hydroxy- Cite This: Chem
    Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue Meeting key synthetic challenges in amanitin synthesis with a new cytotoxic analog: 50-hydroxy- Cite this: Chem. Sci., 2020, 11, 11927 0 † All publication charges for this article 6 -deoxy-amanitin have been paid for by the Royal Society of Chemistry Alla Pryyma, Kaveh Matinkhoo, Antonio A. W. L. Wong and David M. Perrin * Appreciating the need to access synthetic analogs of amanitin, here we report the synthesis of 50-hydroxy- Received 29th July 2020 60-deoxy-amanitin, a novel, rationally-designed bioactive analog and constitutional isomer of a-amanitin, Accepted 2nd October 2020 that is anticipated to be used as a payload for antibody drug conjugates. In completing this synthesis, we DOI: 10.1039/d0sc04150e meet the challenge of diastereoselective sulfoxidation by presenting two high-yielding and rsc.li/chemical-science diastereoselective sulfoxidation approaches to afford the more toxic (R)-sulfoxide. drug-tolerant cell subpopulations.7 Examples include ADCs for Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Introduction targeting human epidermal growth factor receptor 2 and pros- 8 9 a-Amanitin, the deadliest of the amatoxins produced by the tate specic membrane antigen. With but a few exceptions, death-cap mushroom Amanita phalloides, is a potent, orally nearly all bioconjugates to a cytotoxic amanitin have emerged 1 a available inhibitor of RNA polymerase II (pol II) (Ki 10 nM), from naturally-sourced -amanitin. To date, conjugation that has been validated as a payload for targeted cancer handles used for a-amanitin-based bioconjugates include the d- 2a therapy.2 First described in 1907 3 and isolated in 1941,4 a- hydroxyl of (2S,3R,4R)-4,5-dihydroxyisoleucine (DHIle), the 10 0 amanitin is a compact bicyclic octapeptide that has been asparagine side chain, and the 6 -hydroxyl of the tryptathio- 11 indispensable for probing RNA pol II-catalysed transcription in nine staple.
    [Show full text]
  • WSC 2000-01 Conference 1
    The Armed Forces Institute of Pathology Department of Veterinary Pathology WEDNESDAY SLIDE CONFERENCE 2002-2003 CONFERENCE 17 12 February 2003 Conference Moderator: LTC Gary Zaucha, DVM Diplomate, ACVP, ABT, and ACVPM Chief, Department of Comparative Pathology Walter Reed Army Institute of Research Silver Spring, MD 20910 CASE I – 1614-1 (AFIP 2850109) Signalment: 5-month-old outbred female Swiss-Webster mouse History: Sentinel mouse in a laboratory colony housed on dirty bedding from other mouse cages, part of an infectious disease surveillance program. Euthanized due to lethargy and unthriftiness. Gross Pathology: Stomach distended approximately three times by gas, fluid, and partially digested food. Kidneys shrunken, pale, and pitted. Multifocal hemorrhagic necrosis and thrombosis of the ovaries bilaterally. Laboratory Results: Negative for all murine infectious pathogens tested in the colony surveillance program by serology, respiratory and intestinal cultures, fecal examination, anal tape, and skin scrapings. Contributor’s Morphologic Diagnosis: Kidney: Chronic nephropathy characterized by membranous glomerulopathy, lymphoplasmacytic adventitial vasculitis and perivasculitis, tubular degeneration, ectasia, and regeneration with protein, hemoglobin, cellular, waxy, and granular casts, and lymphoplasmacytic and histiocytic interstitial nephritis, severe. Contributor’s Comment: This case is consistent with the previously reported syndrome of gastric dilatation and chronic nephropathy in mice exposed to dirty bedding [1]. Although the mean age of affected mice in the published report was 10 months, similar lesions are sometimes found in animals as young as 3 or 4 months of age. The kidney disease appears immune-mediated and is presumably the result of chronic high antigen exposure, although there may be more than one inciting process.
    [Show full text]
  • Determination of Mushroom Toxin Alpha-Amanitin in Serum by Liquid Chromatography-Mass Spectrometry After Solid-Phase Extraction
    Original article UDC: 615.918:582.28 doi:10.5633/amm.2015.0102 DETERMINATION OF MUSHROOM TOXIN ALPHA-AMANITIN IN SERUM BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY AFTER SOLID-PHASE EXTRACTION Maja Vujović1,2, Ivana Ilić3, Vesna Kilibarda4 University of Niš, Faculty of Medicine, Department of Pharmacy, Serbia1 Institute of Forensic Medicine, Niš, Serbia2 University of Niš, Faculty of Medicine, Serbia3 Military Medical Academy Belgrade, National Poison Control Centre, Serbia4 Alpha-amanitin is a cyclic peptide which belongs to a large group of mushroom toxins known as amatoxins. Being responsible for the majority of fatal mushroom poisonings, they require rapid detection and excretion from the body fluids. In accordance with these requirements, a simple and an accurate method was developed for successful identification and quantification of alpha-amanitin in serum with electrospray liquid chromatography–mass spectrometry (LC-ESI-MS) after collision-induced dissociation. The method conforms to the established International Conference on Harmonization Q2A/Q2B 1996 guidelines on the validation of analytical methods. Linearity, precision, extraction recovery and stability test on blank serum spiked with alpha-amanitin and stored in different conditions met the acceptance criteria. The obtained calibration curve was linear over the concentration range 5-100 ng/mL with a lower limit of quantification (LOQ) of 5 ng/mL and limit of detection (LOD) of 2.5 ng/mL. The mean intra- and inter-day precision and accuracy were 6.05% and less than ±15% of nominal values, respectively. The neutral solid phase extraction with copolymer hydrophilic–lipophilic balance cartridges was found optimal for sample preparation with the mean recovery of 91.94%.
    [Show full text]
  • A Report on Mushrooms Poisonings in 2018 at the Apulian Regional Poison Center
    Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2020 Sep 03; 8(E):616-622. https://doi.org/10.3889/oamjms.2020.4208 eISSN: 1857-9655 Category: E - Public Health Section: Public Health Disease Control A Report on Mushrooms Poisonings in 2018 at the Apulian Regional Poison Center Leonardo Pennisi1, Anna Lepore1, Roberto Gagliano-Candela2*, Luigi Santacroce3, Ioannis Alexandros Charitos1 1Department of Emergency/Urgent, National Poison Center, Azienda Ospedaliero Universitaria Ospedali Riuniti, Foggia, Italy; 2Department of Interdisciplinary Medicine, Forensic Medicine, University of Bari, Bari, Italy; 3Ionian Department, Microbiology and Virology Lab, University of Bari, Bari, Italy Abstract Edited by: Sasho Stoleski BACKGROUND: The “Ospedali Riuniti’s Poison Center” (Foggia, Italy) provides a 24 h telephone consultation in Citation: Pennisi L, Lepore A, Gagliano-Candela R, Santacroce L, Charitos IA. A Report on Mushrooms clinical toxicology to the general public and health-care professionals, including drug information and assessment of Poisonings in 2018 at the Apulian Regional Poison Center. the effects of commercial and industrial chemical substances, toxins but also plants and mushrooms. It participates Open Access Maced J Med Sci. 2020 Sep 03; 8(E):616-622. in diagnosis and treatment of the exposure to toxins and toxicants, also throughout its ambulatory activity. https://doi.org/10.3889/oamjms.2020.4208 Keywords: Poisoning; Intoxication; Epidemiology; Poison center; Mushroom poisoning METHODS: To report data on the epidemiology of mushroom poisoning in people contacting our Poison Center we *Correspondence: Roberto Gagliano-Candela, made computerized queries and descriptive analyses of the medical records database of the mushroom poisoning Department of Interdisciplinary Medicine, Forensic in the poison center of Foggia from January 2018 to December 2018.
    [Show full text]
  • Poisonous Mushrooms; a Review of the Most Common Intoxications A
    Nutr Hosp. 2012;27(2):402-408 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Poisonous mushrooms; a review of the most common intoxications A. D. L. Lima1, R. Costa Fortes2, M. R.C. Garbi Novaes3 and S. Percário4 1Laboratory of Experimental Surgery. University of Brasilia-DF. Brazil/Paulista University-DF. Brazil. 2Science and Education School Sena Aires-GO/University of Brasilia-DF/Paulista University-DF. Brazil. 3School of Medicine. Institute of Health Science (ESCS/FEPECS/SESDF)/University of Brasilia-DF. Brazil. 4Institute of Biological Sciences. Federal University of Pará. Brazil. Abstract HONGOS VENENOSOS; UNA REVISIÓN DE LAS INTOXICACIONES MÁS COMUNES Mushrooms have been used as components of human diet and many ancient documents written in oriental coun- Resumen tries have already described the medicinal properties of fungal species. Some mushrooms are known because of Las setas se han utilizado como componentes de la their nutritional and therapeutical properties and all over dieta humana y muchos documentos antiguos escritos en the world some species are known because of their toxicity los países orientales se han descrito ya las propiedades that causes fatal accidents every year mainly due to medicinales de las especies de hongos. Algunos hongos misidentification. Many different substances belonging to son conocidos por sus propiedades nutricionales y tera- poisonous mushrooms were already identified and are péuticas y de todo el mundo, algunas especies son conoci- related with different symptoms and signs. Carcino- das debido a su toxicidad que causa accidentes mortales genicity, alterations in respiratory and cardiac rates, cada año, principalmente debido a errores de identifica- renal failure, rhabidomyolisis and other effects were ción.
    [Show full text]
  • AMATOXINS in EDIBLE MUSHROOMS H. FAULSTICH* And
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 64, number I FEBS LETTERS April 1976 AMATOXINS IN EDIBLE MUSHROOMS H. FAULSTICH* and M. COCHET-MEILHAC** Max-Planck-Institut fiir medizinische Forschungp Abteilung Naturstoff-Chemie, Jahnstr. 29, D-69 Heidelberg, F. R. G., and **Institut de Chimie Biologique, Unit& de Recherche sur le Cancer de I’INSERM et Centre de Neurochimie du C.N.R.S., FacultP de Midecine, F-67085 Strasbourg, France Received 9 February 1976 1. Introduction 2. Materials and methods The toxic cyclopeptides in Amanita phalloides All mushrooms of the Amanita species, except mushrooms weigh about 0.05% of the fresh tissue. A. rubescens and A. pantherina, were harvested near Two-thirds of this weight are phallotoxins, mostly the Trento (Italy) in 1974. The others were collected acidic compounds phallacidin and phallisacin [ 1,2] , near Heidelberg in 1975. The tissues (20-80 g) were the rest being amatoxins, predominantly cr-amanitin. homogenized in a Star mixer together with a two-fold A combination of chromatographic procedures [3] volume of methanol and then kept under stirring at permits the spectrophotometric determination of up 70°C for 1 h. After centrifugation the supernatant to 11 toxic compounds [4] in single mushrooms. The was evaporated in vacua. The residues were thoroughly sensitivity of this analysis is limited to 0.1 pg of each dried, washed with dry ether and dissolved in 2 ml of toxin, this being sufficient, however, to determine 5 water. The amatoxins were extracted from these different amatoxins in A.
    [Show full text]
  • Determination of Mushroom Toxin Alpha-Amanitin in Serum by Liquid Chromatography-Mass Spectrometry After Solid-Phase Extraction
    Original article UDC: 615.918:582.28 doi:10.5633/amm.2015.0102 DETERMINATION OF MUSHROOM TOXIN ALPHA-AMANITIN IN SERUM BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY AFTER SOLID-PHASE EXTRACTION Maja Vujović1,2, Ivana Ilić3, Vesna Kilibarda4 University of Niš, Faculty of Medicine, Department of Pharmacy, Serbia1 Institute of Forensic Medicine, Niš, Serbia2 University of Niš, Faculty of Medicine, Serbia3 Military Medical Academy Belgrade, National Poison Control Centre, Serbia4 Alpha-amanitin is a cyclic peptide which belongs to a large group of mushroom toxins known as amatoxins. Being responsible for the majority of fatal mushroom poisonings, they require rapid detection and excretion from the body fluids. In accordance with these requirements, a simple and an accurate method was developed for successful identification and quantification of alpha-amanitin in serum with electrospray liquid chromatography–mass spectrometry (LC-ESI-MS) after collision-induced dissociation. The method conforms to the established International Conference on Harmonization Q2A/Q2B 1996 guidelines on the validation of analytical methods. Linearity, precision, extraction recovery and stability test on blank serum spiked with alpha-amanitin and stored in different conditions met the acceptance criteria. The obtained calibration curve was linear over the concentration range 5-100 ng/mL with a lower limit of quantification (LOQ) of 5 ng/mL and limit of detection (LOD) of 2.5 ng/mL. The mean intra- and inter-day precision and accuracy were 6.05% and less than ±15% of nominal values, respectively. The neutral solid phase extraction with copolymer hydrophilic–lipophilic balance cartridges was found optimal for sample preparation with the mean recovery of 91.94%.
    [Show full text]
  • Amanita Phalloides Poisoning: Mechanisms of Toxicity and Treatment
    Food and Chemical Toxicology 86 (2015) 41–55 Contents lists available at ScienceDirect Food and Chemical Toxicology journal homepage: www.elsevier.com/locate/foodchemtox Review Amanita phalloides poisoning: Mechanisms of toxicity and treatment Juliana Garcia a,∗, Vera M. Costa a, Alexandra Carvalho b, Paula Baptista c,PaulaGuedesde Pinho a, Maria de Lourdes Bastos a, Félix Carvalho a,∗∗ a UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua José Viterbo Ferreiran° 228, 4050-313 Porto, Portugal b Department of Cell and Molecular Biology, Computational and Systems Biology, Uppsala University, Biomedical Center, Box 596, 751 24 Uppsala, Sweden c CIMO/School of Agriculture, Polytechnique Institute of Bragança, Campus de Santa Apolónia, Apartado 1172, 5301-854 Bragança, Portugal article info abstract Article history: Amanita phalloides, also known as ‘death cap’, is one of the most poisonous mushrooms, being involved Received 10 April 2015 in the majority of human fatal cases of mushroom poisoning worldwide. This species contains three main Received in revised form 8 September 2015 groups of toxins: amatoxins, phallotoxins, and virotoxins. From these, amatoxins, especially α-amanitin, Accepted 10 September 2015 are the main responsible for the toxic effects in humans. It is recognized that α-amanitin inhibits RNA Available online 12 September 2015 polymerase II, causing protein deficit and ultimately cell death, although other mechanisms are thought Keywords: to be involved. The liver is the main target organ of toxicity, but other organs are also affected, especially Amanita phalloides the kidneys. Intoxication symptoms usually appear after a latent period and may include gastrointestinal Amatoxins disorders followed by jaundice, seizures, and coma, culminating in death.
    [Show full text]
  • | Hai Lala Mo at Alt a La La La Manual
    |HAI LALA MO ATUS009938323B2 ALT A LA LA LA MANUAL (12 ) United States Patent ( 10 ) Patent No. : US 9 ,938 , 323 B2 Grunewald et al. (45 ) Date of Patent : Apr . 10 , 2018 ( 54 ) AMATOXIN DERIVATIVES AND WO 2014135282 AL 9 / 2014 CONJUGATES THEREOF AS INHIBITORS WO 2014141094 Al 9 / 2014 OF RNA POLYMERASE WO 2016142049 AL 9 / 2016 (71 ) Applicant: NOVARTIS AG , Basel (CH ) OTHER PUBLICATIONS ( 72 ) Inventors : Jan Grunewald , San Diego , CA (US ) ; Yunho Jin , San Diego , CA (US ) ; Zhao , et al ., “ Synthesis of a Cytotoxic Amanitin for Biorthogonal Weijia Ou , San Diego , CA (US ) ; Conjugation ” , ChemBioChem , 2015 , pp . 1420 - 1425, vol . 16 , Tetsuo Uno , San Diego , CA (US ) Wiley - VCH Verlag GmbH & Co . Adair, et al ., “ Antibody -drug conjugates a perfect synergy ” , ( 73 ) Assignee : Novartis AG , Basel (CH ) Expert Opin . Biol. Ther. , 2012 , pp . 1191 - 1206 , vol. 12 , No . 9 , Informa UK , Ltd . ( * ) Notice : Subject to any disclaimer , the term of this Flygare , et al ., “ Antibody - Drug Conjugates for the Treatment of patent is extended or adjusted under 35 Cancer ” , Chem . Biol . Drug . Des. , 2013 , pp . 113 - 121 , vol. 81 , John Wiley & Sons A / S . U . S . C . 154 ( b ) by 0 days . Jackson , et al ., “ Using the Lessons Learned from the Clinic to Improve the Preclinical Development of Antibody Drug Conju (21 ) Appl. No. : 15 /524 , 197 gates ” , Pharm . Res . , 2014 , pp . 1 - 12 . (22 ) PCT Filed : Nov. 5 , 2015 (Continued ) ( 86 ) PCT No. : PCT/ IB2015 /058537 Primary Examiner — Jeanette Lieb $ 371 ( c ) ( 1 ) , ( 74 ) Attorney , Agent, or Firm — Daniel E . Raymond ; ( 2 ) Date : May 3, 2017 Genomics Institute of the Novartis Research Foundation ( 87) PCT Pub .
    [Show full text]
  • Deactivation Study of Α-Amanitin Toxicity in Poisonous Amanita Spp
    orensi Narongchai and Narongchai, J Forensic Res 2017, 8:6 f F c R o e l s a e n DOI: 10.4172/2157-7145.1000396 r a r u c o h Journal of J ISSN: 2157-7145 Forensic Research Research Article Open Access Deactivation Study of α-Amanitin Toxicity in Poisonous Amanita spp. Mushrooms by the Common Substances In Vitro Paitoon Narongchai* and Siripun Narongchai Department of Forensic Medicine, Faculty of Medicine, ChiangMai University, Chiang Mai, Thailand Abstract The purpose of this research was to find out the substance which deactivate α-AmanitinToxicity The materials and methods used in the study include analysis with high performance liquid chromatography (HPLC) to: 1.Demonstrate the standard α-amanitin at concentrations of 25, 50 and 100 µg/ml 2.Determine the deactivation of α-amanitin with 1) 18% acetic acid 2), calcium hydroxide 40 mg/ml, 3) potassium permanganate 20 mg/ml, 4) sodium bicarbonate 20 mg/ml 3.Report the statistical analysis as the mean ± standard deviation (SD) and paired t-test. The result revealed that potassium permanganate could eliminate 100 percent of the α-amanitin at 25, 50 and 100 µg/ml. Calcium hydroxide, sodium bicarbonate and acetic acid had lower elimination rates at those concentrations: 68.43 ± 2.58 (-71.4, -67.2, -66.7%), 21.48 ± 10.23 (-29.4, -25.2, -9.9%) and 3.21 ± 0.02% (-3.2, -3.2, +1.1%), respectively. The conclusion of this study was suggested that potassium permanganate could be applied as an absorbent substance during gastric lavage in patients with mushroom poisoning.
    [Show full text]
  • Identification of Forensically Relevant Oligopeptides of Poisonous Mushrooms with Capillary Electrophoresis-ESI-Mass Spectrometry
    Identification of forensically relevant oligopeptides of poisonous mushrooms with capillary electrophoresis-ESI-mass spectrometry J. Rittgen, M. Pütz, U. Pyell Abstract Over 90% of the lethal cases of mushroom toxin poisoning in man are caused by a species of Amanita. They contain the amatoxins α-, β-, γ- and ε-amanitin, amanin and amanullin together with phallotoxins and virotoxins. The identification of the named toxicants in intentionally poisoned samples of foodstuff and beverages is of significant forensic interest. In this work a CE-ESI-MS procedure was developed for the separation of five forensically relevant oligopeptides including α-, β- and γ-amanitin, phalloidin and phallacidin. The running buffer consisted of 20 mmol/l ammonium formate at pH 10.8 and 10% (v/v) isopropanol. Dry nitrogen gas was delivered at 4 l/min at 250°C. The pressure of nebulizing nitrogen gas was set at 4 psi. The sheath liquid was isopropanol/water (50:50, v/v) at a flow rate of 3 µl/min. A mass range between 600 and 1000 m/z and negative as well as positive polarity detection mode was selected. The separation of the five negatively charged analytes was achieved at 23°C within 8 min using a high voltage of + 28 kV. The method validation included the determination of the detection limits (10 – 40 ng/ml) and the repeatability of migration time (0.2 – 0.3% RSD). The CE-MS procedure was successfully applied for the identification of amatoxins and phallotoxins in extracts of fresh and dried mushroom samples. 1. Introduction Over 90% of the lethal cases of mushroom toxin poisoning in man are caused by a species of Amanita [1].
    [Show full text]
  • Conceptual DFT As a Novel Chemoinformatics Tool for Studying
    Open Chem. 2019; 17:1133–1139 Research Article Norma Flores-Holguín, Juan Frau, and Daniel Glossman-Mitnik* Conceptual DFT as a Novel Chemoinformatics Tool for Studying the Chemical Reactivity Properties of the Amatoxin Family of Fungal Peptides https://doi.org/10.1515/chem-2019-0129 Received Sep 12, 2019; accepted Oct 24, 2019 1 Introduction Abstract: The chemical structures and molecular reac- Amatoxins are a group of deadly toxins found in Amanita tivities of the Amatoxin group of fungi-derived peptides fungi consisting of nine octapeptides with a bicycle struc- have been determined by means of the consideration of ture which are named as α-amanitin, β-amanitin, 훾- a model chemistry that has been previously validated as amanitin, ϵ-amanitin, amanullinic acid, amanin, amani- well-behaved for our purposes. The reactivity descriptors namide, amanullin and proamanullin. These toxins are of- were calculated on the basis of a methodological frame- ten associated with another group of bicyclic peptides, the work built around the concepts that are the outcome of the phallotoxins, which only contain seven amino acids in the so called Conceptual Density Functional Theory (CDFT). ring [1]. This procedure in connection with the different Fukui func- Amatoxins are found in mushrooms of the genera tions allowed to identify the chemically active regions Amanita, Galerina, Lepiota, and Conocybe from the fungal within the molecules. By considering a simple protocol phylum Basidiomycetes. α-amanitin poisoning causes irre- designed by our research group for the estimation of the versible liver damage and is responsible for 90% of fatal pKa of peptides through the information coming from the incidents with mushrooms.
    [Show full text]